Amicus Therapeutics to Present at UBS Global Healthcare Conference

Amicus Therapeutics to Present at UBS Global Healthcare Conference  CRANBURY, N.J., May 14, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that William D. "Chip" Baird, Chief Financial Officer, will present a corporate overview at the UBS Global Healthcare Conference on Wednesday, May 21, 2014 at 12:00 p.m. ET.  A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.  About Amicus Therapeutics  Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.  FOLD-G  CONTACT: Amicus Therapeutics          Sara Pellegrino          (609) 662-5044          spellegrino@amicusrx.com